Related references
Note: Only part of the references are listed.Connexins, gap junctions and tissue invasion
Norah Defamie et al.
FEBS LETTERS (2014)
Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments
Xiaonan Zhang et al.
NATURE COMMUNICATIONS (2014)
Novel Chelators for Cancer Treatment: Where Are We Now?
Angelica M. Merlot et al.
ANTIOXIDANTS & REDOX SIGNALING (2013)
Mammalian Iron Homeostasis in Health and Disease: Uptake, Storage, Transport, and Molecular Mechanisms of Action
Alfons Lawen et al.
ANTIOXIDANTS & REDOX SIGNALING (2013)
Ribonucleotide Reductase Expression in Cervical Cancer A Radiation Therapy Oncology Group Translational Science Analysis
Charles A. Kunos et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2013)
Antitumor Activity of Metal-Chelating Compound Dp44mT Is Mediated by Formation of a Redox-Active Copper Complex That Accumulates in Lysosomes
David B. Lovejoy et al.
CANCER RESEARCH (2011)
Novel Thiosemicarbazones of the ApT and DpT Series and Their Copper Complexes: Identification of Pronounced Redox Activity and Characterization of Their Antitumor Activity
Patric J. Jansson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Resistance to chemotherapy in cancer: A complex and integrated cellular response
Howard R. Mellor et al.
PHARMACOLOGY (2008)
Phase II study of triapinea® in patients with metastatic renal cell carcinoma:: A trial of the national cancer institute of canada clinical trials group (NCIC IND.161)
Jennifer J. Knox et al.
INVESTIGATIONAL NEW DRUGS (2007)
A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics
Megan Whitnall et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
A ferrous-Triapine complex mediates formation of reactive oxygen species chat inactivate human ribonucleotide reductase
JM Shao et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Repopulation of cancer cells during therapy: An important cause of treatment failure
JJ Kim et al.
NATURE REVIEWS CANCER (2005)
Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment
J Yuan et al.
BLOOD (2004)
Iron chelators as therapeutic agents for the treatment of cancer
DR Richardson
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2002)
Hypoxia - A key regulatory factor in tumour growth
AL Harris
NATURE REVIEWS CANCER (2002)
Hypoxia inhibits G1/S transition through regulation of p27 expression
LB Gardner et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Tumor physiology and drug resistance
IF Tannock
CANCER AND METASTASIS REVIEWS (2001)
Iron homeostasis: Insights from genetics and animal models
NC Andrews
NATURE REVIEWS GENETICS (2000)
Triapine (3-aminopyridine-2-carboxaldehydethiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity
RA Finch et al.
BIOCHEMICAL PHARMACOLOGY (2000)
Share Paper
